2019-01-07 14:14:02
Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. This study was a meta-analysis of trials (1). The results showed that eighteen studies involving 1424 patients were included. The authors found a significant benefit for ω-3 PUFAs vs control for liver fat, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglycerides, insulin resistance, and glucose. However, there was significant interstudy heterogeneity. The authors conclude that ω-3 PUFA supplementation may decrease liver fat and hepatic enzyme parameters.
[collapsed title=”Reference:”]
- Yan JH, et al. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(37):e12271.
[/collapsed]